|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2009-6-29
|
|
pubmed:abstractText |
Clinical trials using 80 mg once weekly pegvisomant (pegV) in active acromegaly led to a 30% fall in serum IGF1. Subsequent studies demonstrated that daily administration of up to 40 mg/day achieved an IGF1 within reference range in 97% of patients. PegV has a half-life of >70 h suggesting weekly dosing may be possible but using higher doses than in the initial trials.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1479-683X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
161
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
21-5
|
|
pubmed:meshHeading |
pubmed-meshheading:19411301-Acromegaly,
pubmed-meshheading:19411301-Drug Administration Schedule,
pubmed-meshheading:19411301-Female,
pubmed-meshheading:19411301-Human Growth Hormone,
pubmed-meshheading:19411301-Humans,
pubmed-meshheading:19411301-Insulin-Like Growth Factor I,
pubmed-meshheading:19411301-Male,
pubmed-meshheading:19411301-Middle Aged,
pubmed-meshheading:19411301-Prospective Studies,
pubmed-meshheading:19411301-Quality of Life,
pubmed-meshheading:19411301-Receptors, Somatotropin,
pubmed-meshheading:19411301-Treatment Outcome
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Successful use of weekly pegvisomant administration in patients with acromegaly.
|
|
pubmed:affiliation |
Department of Endocrinology, The Christie Hospital, Manchester M204BX, UK.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
